

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Medical & HealthCare Group Limited

(Incorporated in Bermuda with limited liability)

(Stock Code: 383)

PROFIT WARNING SUPPLEMENTAL ANNOUNCEMENT

This announcement is made by China Medical & HealthCare Group Limited (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the announcement of the Company dated 20 January 2023 in relation to the profit warning of the Company (the “**Profit Warning Announcement**”). Unless otherwise specified, capitalized terms used herein shall have the same meaning as those defined in the Profit Warning Announcement.

The Board wishes to further inform the shareholders of the Company and potential investors that based on its preliminary review on the relevant unaudited consolidated management accounts of the Group for the year ended 31 December 2022 and information currently available, the Group is expected to record the Net Loss for the year ended 31 December 2022 which represents (a) an approximately 5% to 35% decrease when compared with the Net Loss for the year ended 31 December 2021; but (b) an approximately 65% to 95% increase when compared with the Net Loss for the year ended 31 December 2021 excluding the one-off non-recurring item of impairment loss under expected credit loss model recognized on loan receivable. This was mainly due to the adverse factors set out in the Profit Warning Announcement and further to (i) the loss on fair value changes on investment properties compared with a gain recorded for the year ended 31 December 2021; (ii) the provision for properties under development for sale and properties held for sale; and (iii) the written-off of property plant and equipment.

This profit warning supplemental announcement is only based on the preliminary review on the relevant unaudited consolidated management accounts of the Group for the year ended 31 December 2022 and information currently available, which have not been confirmed or reviewed by the auditor of the Company, and may be subject to adjustments. The Company is in the process of finalizing the annual results for the year ended 31 December 2022 and shareholders of the Company and potential investors are advised to read carefully the annual results announcement of the Company for the year ended 31 December 2022, which is expected to be released before the end of March 2023.

Shareholders of the Company and potential investors should exercise caution when dealing in the securities of the Company.

By Order of the Board
China Medical & HealthCare Group Limited
Chong Sok Un
Deputy Chairman

Hong Kong, 17 March 2023

As at the date of this announcement, the Board comprises:-

Executive Directors

Ms. Chong Sok Un (Deputy Chairman), Mr. Kong Muk Yin, Mr. Guo Meibao and Mr. Zhou Haiying

Non-Executive Directors

Mr. Lai Hin Wing Henry Stephen and Mr. Gao Zhaoyuan

Independent Non-Executive Directors

Mr. Zhang Jian, Dr. Xia Xiaoning, Dr. Wong Wing Kuen, Albert and Ms. Yang Lai Sum, Lisa